Skip to main content

Table 1 Patient characteristics according to sTIL categories. sTIL categories were defined as “low sTILs” (0–10% sTILs), “intermediate sTILs” (11–50% sTILs), and “high sTILs” (51–100% sTILs)

From: Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

 

All

Low sTILs (valid %)

Intermediate sTILs (valid %)

High sTILs (valid %)

p value, chi-square

Tumor stage

pT1

1499

1232 (82.2)

218 (14.5)

49 (3.3)

.760

pT22

1088

885 (81.5)

163 (15.0)

38 (3.5)

 

pT3

89

75 (84.3)

13 (14.6)

1 (1.1)

 

pT4

17

16 (94.1)

1 (5.9)

0 (0.0)

 

Nodal status

pN0

1843

1499 (81.3)

274 (14.9)

70 (3.8)

.021

pN1

978

829 (84.8)

130 (13.3)

19 (1.9)

 

pN2–3

172

143 (831)

27 (15.7)

2 (1.2)

 

ER (local)

Negative

445

256(57.5)

143 (32.1)

46 (10.3)

< .001

Positive

2246

1952 (86.9)

252 (11.2)

42 (1.9)

 

PR local

Negative

625

399 (63.8)

172 (27.5)

54 (8.6)

< .001

Positive

2066

1809 (87.6)

223 (10.8)

34 (1.6)

 

Local HR status

Negative

419

236 (56.3)

138 (32.9)

45 (10.7)

< .001

Positive

2574

2235 (86.8)

293 (11.4)

46 (1.8)

 

Age at registration

≤ 50

984

794 (80.7)

163 (16, 6)

27 (2.7)

.055

> 50

2009

1677 (83.5)

268 (13.3)

64 (3.2)

 

Ki67 expression

1–15

1040

959 (92.2)

76 (7.3)

5 (0.5)

< .001

15–34

1383

1113 (80.5)

223 (16.1)

47 (3.4)

 

35–100

305

159 (52.1)

112 (36.7)

34 (11.1)

 

Recurrence Score

Low (0–11)

449

423 (94.2)

25 (5.6)

1 (0.2)

< .001

Intermediate (12–25)

1509

1345 (89.1)

146 (9.7)

18 (1.2)

 

High (26–99)

546

407 (74.5)

112 (20.5)

27 (4.9)